Durect and innocoll announce a $136 million u.s. licensing agreement for posimir® (bupivacaine solution)

Cupertino, calif. and athlone, ireland, dec. 22, 2021 /prnewswire/ -- durect corporation (nasdaq: drrx) today announced a licensing agreement granting innocoll biotherapeutics plc, a specialty pharmaceutical company and portfolio business of gurnet point capital, exclusive development and commercialization rights to posimir® (bupivacaine solution) for infiltration use, durect's fda-approved non-opioid, sustained-release local analgesic for the treatment of post-surgical pain in adults following arthroscopic subacromial decompression surgery, in the united states.
DRRX Ratings Summary
DRRX Quant Ranking